What are your wishes and needs for networking? And how is this changed due to the COVID-19 pandemic? We are eager to hear your view! Complete the survey here to help us improve the Networking Support Scheme, the EJP RD funding opportunity for networking. Please note: if you are a principal applicant or an evaluator…
The European Joint Programme on Rare Diseases has launched an academic education course on rare diseases research topics. The development of the courses is coordinated by the Foundation for Rare Diseases, one of the EJP RD partners. The first course will address research issues related to diagnosis in the rare diseases context. More information Join…
The Big Data Steering Group has launched an initiative to develop a Data Standards Strategy that will enable the Network to more effectively leverage data to deliver evidence in support of benefit-risk decision-making on the development, authorisation and use of medicines. If you are part of Patients’ & Healthcare Professionals’ organisations or a Learned Societies, the European…
The Rare Disease Cures Accelerator–Data and Analytics Platform is launching a new webinar series with the goal of sharing with the community examples of the use of rare disease person-level data in drug development and regulatory decision making. The series will feature 1-hour webinars highlighting analyses that have been done in individual disease areas, how…
The 1st International Conference on Rare Diseases was held on the 1st and 2nd of March online. The event was a great success and was attended by more than 650 participants from 37 countries around the world (Europe, USA and Asia) including health professionals, researchers, academics, policy makers, industry representatives and patients. For the first…
VISION-DMD published a white paper on how to return individual clinical trial results back to patients. It focuses on addressing the ethical and technical challenges, using the vamorolone clinical trial experience. In short: Often, individual patient data is not returned to the participants, even when this is requested. ReveraGen received a grant to develop an…
We are glad to pre-announce the upcoming opening of the call for Research Mobility Fellowships on the 15th of March, which aims to support PhD students, Postdocs and medical doctors in training to undertake scientific visits fostering specialist research training outside their countries of residence. The exchange can be carried out within the same ERN…
EMA has recommended granting a marketing authorisation in the European Union for the first treatment that can be given orally to patients with certain types of spinal muscular atrophy (SMA), a rare and often fatal genetic disease that causes muscle weakness and progressive loss of movement. Evrysdi is indicated for the treatment of 5q SMA…
Happy Rare Disease Day! Watch EJP RD contributors answer the web’s most search questions about rare diseases in a new video that you can find HERE (subtitles available). Like every year, EJP RD is proud to contribute to spreading awareness on Rare Disease Day. Don’t forget to share the video and subscribe to our Youtube channel and to our Twitter to be kept updated on our funding opportunities,…
(Pre-proposal deadline: 31 March 2021) Angelini Pharma is an international group, leader in health care and well-being, committed to help patients, doctors and caregivers in the fight against diseases with constant and prevalent attention in the areas of Pain and Inflammation and Mental Health. Angelini Pharma has made research its core business to improve patients’…